Aquestive Therapeutics IncAQST
Price$4.63

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $54.1M-6.0% YoYTTM through 30 Jun 2026
Net Income -$78.2MTTM through 30 Jun 2026
Free Cash Flow -$45.9MTTM through 30 Jun 2026

Margins

Current
Gross Margin76.0%
EBITDA Margin-96.6%
Operating Margin-29.1%
Net Margin-144.6%

Returns

138.2%ROE
-59.2%ROA

Balance Sheet Health

Debt / Equity-0.97x
Current Ratio4.10x
Net Debt-$65.7Mnet cash position
Cash & Equivalents$98.5M

Quality Metrics

Altman Z-Score-3.07
Piotroski F-Score3 / 9
FCF Margin-85.0%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $44.5M
Diluted EPS-$0.66TTM
'20'21'22'23'24'25
FY2025: $-0.78

Dividend

No dividend

Capital Allocation

R&D Spend$15.9M
Capex Intensity1.1%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.